Vimarsana
Biggest News Aggregation in the World

Page 5 - Mark Leiser News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Leiser. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Leiser Today - Breaking & Trending Today

Warrensburg Woman Dies in JoCo Crash - Vimarsana News

Warrensburg Woman Dies in JoCo Crash

A Warrensburg woman died after an SUV collided with a van in Johnson County Saturday morning.

MISSOURI STATE HIGHWAY PATROL REPORTS EIGHT FATALITIES OVER THANKSGIVING HOLIDAY - Vimarsana News

MISSOURI STATE HIGHWAY PATROL REPORTS EIGHT FATALITIES OVER THANKSGIVING HOLIDAY

MISSOURI STATE HIGHWAY PATROL REPORTS EIGHT FATALITIES OVER THANKSGIVING HOLIDAY

Source: kmmo.com
The University of Texas MD Anderson Cancer Center names vice president for research - Vimarsana News

The University of Texas MD Anderson Cancer Center names vice president for research

Eyal Gottlieb, PhD, has been named vice president for research at The University of Texas MD Anderson Cancer Center. Gottlieb will oversee laboratory science departments that lead discovery and translational research across multiple disciplines. He will work closely with various MD Anderson staff to implement the university’s scientific research strategy.

Source: healio.com
Shared decision-making required when choosing first-line regimen for PD-L1-high NSCLC - Vimarsana News

Shared decision-making required when choosing first-line regimen for PD-L1-high NSCLC

CHICAGO — Chemoimmunotherapy and immunotherapy alone conferred comparable benefit as first-line therapy for most patients with advanced non-small cell lung cancer and high PD-L1 expression, results presented at ASCO Annual Meeting showed.Older patients appeared to derive better OS and PFS outcomes with immunotherapy alone, findings from the exploratory pooled analysis showed.

Source: healio.com
First-line brentuximab vedotin regimen extends OS in advanced classical Hodgkin lymphoma - Vimarsana News

First-line brentuximab vedotin regimen extends OS in advanced classical Hodgkin lymphoma

CHICAGO — The addition of brentuximab vedotin to frontline chemotherapy significantly extended OS among patients with advanced classical Hodgkin lymphoma, according to study results presented at ASCO Annual Meeting.The experimental regimen conferred a 41% reduction in risk for death compared with standard chemotherapy, updated results of the randomized phase 3 ECHELON-1 trial showed.

Source: healio.com